Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10608121 | 0.83 | CPN1 (0.41) | CPN1CPB2 | |
| SCHEMBL4290504 | 0.81 | CPN1 (0.41) | CPN1CPB2NOS2 | |
| SCHEMBL4290481 | 0.81 | CPN1 (0.41) | CPN1CPB2NOS2 | |
| SCHEMBL10608177 | 0.77 | CPN1 (0.44) | CPN1CPB2NOS2LMNASMN1; SMN2 | |
| SCHEMBL9341469 | 0.76 | SIGMAR1 (0.39) | CPN1CPB2 | |
| SCHEMBL28733804 | 0.75 | TP53 (0.45) | LMNAEPHX2SMN1; SMN2 | |
| SCHEMBL28733911 | 0.75 | TP53 (0.45) | LMNAEPHX2SMN1; SMN2 | |
| SCHEMBL5612541 | 0.73 | REN (0.36) | RENMAPK1OPRK1HTR2A | |
| SCHEMBL3937383 | 0.73 | CPN1 (0.46) | CPN1CPB2NOS2LMNASMN1; SMN2 | |
| SCHEMBL968621 | 0.73 | CPN1 (0.35) | CPN1CPB2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858624-B2 | Piperidine and morpholine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | CPN1 63/4885CPB2 31/4885REN 1/4885 |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | REN, ACE, PREP | CPN1 252/4885CPB2 96/4885REN 1/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | CPN1 55/4885CPB2 31/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.